Sign in Subscribe
Cancer research

Promising "Off-the-Shelf" Immunotherapy Approach for Acute Myeloid Leukemia Patients

Strategic Insights

— 1 min read

Fresh data on Oncology - Acute Myeloid Leukemia have been presented in a new report. According to research from the University of Texas MD Anderson Cancer Center, Donor-Derived Vg9Vd2 T cells are a promising candidate for treating patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. The researchers investigated the feasibility of using donor-derived Vg9Vd2 T cells to treat AML as both a single agent and in combination with venetoclax. They observed that Vg9Vd2 T cells efficiently induced apoptosis in AML cells from eight cell lines and three primary cultures in an effector-to-target cell ratio-dependent manner. Moreover, Vg9Vd2 T cells showed potent cytotoxicity against the venetoclax-resistant OCI-AML3 cell line and remained potent in the presence of venetoclax.

Key Takeaways:

  • Donor-Derived Vg9Vd2 T cells are a promising "off-the-shelf" immunotherapy approach for AML patients, especially those with venetoclax-resistant disease.
  • The researchers observed that replenishing patients with Vd2 T cells may be an effective treatment option due to their good safety profile and cytotoxic effects in various types of cancers.
  • The study found that donor-derived Vg9Vd2 T cells efficiently induced apoptosis in AML cells from eight cell lines and three primary cultures.
  • The researchers observed an additive effect of venetoclax and Vg9Vd2 T cells in a xenograft model established with the venetoclax-resistant OCI-AML3 cell line.
  • The study suggests that Vg9Vd2 T cells may be effective in treating AML patients who have failed previous treatments or have, venetoclax-resistant disease.

Statistics:

  • The research used flow cytometry to profile the subtype and memory phenotype of peripheral blood gd T cells in AML patients.
  • The study observed that Vd2 T cells were less abundant and the TEMRA phenotype was more prevalent in AML patients compared to healthy donors.
  • The researchers found that Vg9Vd2 T cells efficiently induced apoptosis in AML cells from eight cell lines and three primary cultures in an effector-to-target cell ratio-dependent manner.
  • The study showed that donor-derived Vg9Vd2 T cells remained potent in the presence of venetoclax.
  • The researchers observed an additive effect of venetoclax and Vg9Vd2 T cells in a xenograft model established with the venetoclax-resistant OCI-AML3 cell line.

Sources:

  • Donor-Derived Vg9Vd2 T Cells for Acute Myeloid Leukemia: A Promising "Off-the-Shelf" Immunotherapy Approach. Cancers, 2025;17(19):3166.

Read more